Display Settings:

Format

Send to:

Choose Destination
    Ecancermedicalscience. 2012;6:240. Epub 2012 Jan 3.

    Pregnant with metastatic neuroendocrine tumour of the ovary: what now?

    Source

    Department of Medical Oncology, Ospedale di Macerata and Fertility and Procreation in Oncology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy.

    Abstract

    Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms commonly occurring in the gastrointestinal tract or lungs but can occur in other regions. Primary ovarian NET account for 5% of all NET and 0.1% of all ovarian malignancies. In metastatic disease, the therapeutic goal is to extend survival and to improve quality of life. As these tumours express somatostatin receptors, somatostatin analogues are frequently used to control symptoms. Here we present a case of a pregnant woman with an ovarian NET with liver metastases and carcinoid syndrome who was treated with the somatostatin analogue, Octreotide LAR. We also summarize reported data of the use of somatostatin analogues during pregnancy.

    PMID:
    22331988
    [PubMed - in process]
    PMCID:
    PMC3273852
    Free PMC Article

    Images from this publication.See all images (1) Free text

    Figure 1:

      Supplemental Content

      Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk